William Blair Issues Negative Outlook for Medpace Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) – Analysts at William Blair reduced their Q3 2025 earnings per share estimates for Medpace in a report released on Tuesday, February 11th. William Blair analyst M. Smock now anticipates that the company will post earnings of $2.99 per share for the quarter, down from their prior estimate of $3.18. William Blair has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.93 per share. William Blair also issued estimates for Medpace’s Q4 2025 earnings at $2.93 EPS, FY2025 earnings at $12.12 EPS, Q1 2026 earnings at $3.38 EPS, Q2 2026 earnings at $3.44 EPS, Q3 2026 earnings at $3.50 EPS and Q4 2026 earnings at $3.57 EPS.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%.

Several other equities analysts have also commented on the company. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird upped their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Finally, TD Cowen decreased their price target on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Medpace presently has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Stock Up 1.8 %

Shares of Medpace stock opened at $342.41 on Thursday. Medpace has a 52 week low of $302.01 and a 52 week high of $459.77. The business’s fifty day simple moving average is $343.70 and its 200-day simple moving average is $348.88. The firm has a market cap of $10.64 billion, a PE ratio of 29.98, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36.

Institutional Investors Weigh In On Medpace

Institutional investors and hedge funds have recently modified their holdings of the company. Centaurus Financial Inc. increased its holdings in shares of Medpace by 2.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after acquiring an additional 29 shares during the last quarter. Assetmark Inc. increased its holdings in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after acquiring an additional 29 shares during the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Medpace by 4.1% in the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after acquiring an additional 29 shares during the last quarter. Lindbrook Capital LLC increased its holdings in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after acquiring an additional 29 shares during the last quarter. Finally, HBK Sorce Advisory LLC increased its holdings in shares of Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after acquiring an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.